Kinarus Revenue and Competitors
Estimated Revenue & Valuation
- Kinarus's estimated annual revenue is currently $1.2M per year.
- Kinarus's estimated revenue per employee is $201,000
Employee Data
- Kinarus has 6 Employees.
- Kinarus grew their employee count by -50% last year.
Kinarus's People
Name | Title | Email/Phone |
---|
Kinarus Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Kinarus?
Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments, for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus is preparing for a rapid launch of a Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinarus's drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.
keywords:N/AN/A
Total Funding
6
Number of Employees
$1.2M
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kinarus News
Die Verschmelzung von Perfect Holding mit Kinarus kommt voran. Deren Aktionäre haben der Transaktion zugestimmt. Drucken.
Zurich (awp) - Les actionnaires de la société biopharmaceutique bâloise Kinarus ont donné leur accord en vue de son acquisition prévue par...
Kinarus kann ihre Phase-II-Studie an hospitalisierten Coronapatienten weiterführen. Das Gremium, das die Studie überwacht,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 7 | -12% | N/A |
#2 | $0.6M | 8 | 14% | N/A |
#3 | $0.6M | 8 | N/A | N/A |
#4 | $0.4M | 8 | -11% | N/A |
#5 | $2.3M | 9 | -50% | N/A |